The results showed that VRK2 knockdown could induce an increase of ROS and decline of cell viability and GSH following TBHP treatment, while these alterations could be partly reversed by ectopic SLC7A11 expression but not GCLC or GSS expression (Fig
Third, although protective effects were observed in preclinical models, their applicability to human OA remains uncertain, and well-designed clinical trials are necessary to validate these findings
doi: 10.1007/s001250051082
Bertoni S, Albertini B, Facchini C, Prata C, Passerini N
What these mechanisms do NOT prove: that these pathways are activated to the same degree, duration, or tissue specificity in a human taking an oral capsule with unknown systemic bioavailability
Third-Party Testing: Transparency is vital